Published in Medical Letter on the CDC and FDA, May 30th, 2004
The company reported revenues of $1.7 million for the quarter, a net loss of $12.5 million or $0.16 per share, and cash, cash equivalents, and marketable securities totaling $67.5 million.
During the quarter, the U.S. Food and Drug Administration (FDA) accepted the Genasense (oblimersen sodium) Injection new drug application for use in combination with dacarbazine for the treatment of patients with advanced melanoma who have not received prior chemotherapy.
The FDA granted priority review status to the application, which targets an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.